Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease

被引:213
作者
Angelico, F
Del Ben, M
Conti, R
Francioso, S
Feole, K
Fiorello, S
Cavallo, MG
Zalunardo, B
Lirussi, F
Alessandri, C
Violi, F
机构
[1] Univ Roma La Sapienza, Dept Expt Med & Pathol, Div Internal Med 4, I-00161 Rome, Italy
[2] Univ Roma La Sapienza, Div Clin & Appl Med Therapy, I-00161 Rome, Italy
[3] Univ Padua, Dept Med & Surg Sci, I-35100 Padua, Italy
关键词
D O I
10.1210/jc.2004-1024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: An association of nonalcoholic fatty liver disease with the insulin-resistant metabolic syndrome has been suggested. The aim of the study was to assess the association of fatty liver to different degrees of insulin resistance and secretion. Methods and Results: The study was performed in 308 alcohol- and virus-negative consecutive patients attending a metabolic clinic, who underwent a complete clinical and biochemical work-up including oral glucose tolerance test and routine liver ultrasonography. Steatosis was graded as absent/ mild, moderate, and severe. In nondiabetic subjects, a progressive ( P < 0.05) increase in mean homeostasis model of insulin resistance was recorded from the group without steatosis to the groups with mild/moderate and severe steatosis. Severe steatosis was associated with the clustering of the five clinical and biochemical features proposed for the clinical diagnosis of the metabolic syndrome. Subjects with the metabolic syndrome with a more pronounced insulin resistance had a higher prevalence of severe steatosis ( P < 0.01) compared with those with homeostasis model of insulin resistance below the median. Conclusions: The findings stress the heterogeneous presentation of patients with the metabolic syndrome when the diagnosis is based on the broad Adult Treatment Panel III clinical criteria and demonstrate that those who are more insulin resistant have a higher prevalence of severe steatosis.
引用
收藏
页码:1578 / 1582
页数:5
相关论文
共 32 条
[1]   Non-alcoholic fatty liver disease [J].
Alba, LM ;
Lindor, K .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) :977-986
[2]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[3]  
2-S
[4]   NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older [J].
Alexander, CM ;
Landsman, PB ;
Teutsch, SM ;
Haffner, SM .
DIABETES, 2003, 52 (05) :1210-1214
[5]   Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases [J].
Angelico, F ;
Del Ben, M ;
Conti, R ;
Francioso, S ;
Feole, K ;
Maccioni, D ;
Antonini, TM ;
Alessandri, C .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 18 (05) :588-594
[6]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[7]   The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome.: The French DESIR study [J].
Balkau, B ;
Vernay, M ;
Mhamdi, L ;
Novak, M ;
Arondel, D ;
Vol, S ;
Tichet, J ;
Eschwège, E .
DIABETES & METABOLISM, 2003, 29 (05) :526-532
[8]   Prevalence of and risk factors for hepatic steatosis in northern Italy [J].
Bellentani, S ;
Saccoccio, G ;
Masutti, F ;
Crocè, LS ;
Brandi, G ;
Sasso, F ;
Cristanini, G ;
Tiribelli, C .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) :112-117
[9]   Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? [J].
Chitturi, S ;
Farrell, G ;
Frost, L ;
Kriketos, A ;
Lin, R ;
Liddle, C ;
Samarasinghe, D ;
George, J .
HEPATOLOGY, 2002, 36 (02) :403-409
[10]   Hepatic steatosis and type 2 diabetes mellitus. [J].
Clark J.M. ;
Diehl A.M. .
Current Diabetes Reports, 2002, 2 (3) :210-215